Jump to Navigation

Drug Litigation Archives

Avandia Causes Heart Problems

Two studies have found that Avandia (rosiglitazone) creates a risk of heart attacks and strokes. The studies have shown a significant increase in the risk for heart failure, stroke and even death. One study has found that Avandia raises the risk of heart attacks by 28-39% compared with other diabetes medications. In response, some lawmakers have called for Avandia to be pulled from the market. If you are looking for a Houston Avandia lawyer , please contact us.

Blood Pressure Drugs Linked to Cancer

Blood pressure medications known as "angiotensin-receptor blockers" may increase the risk of cancer. An analysis of five studies revealed an increase of eleven percent in cancer overall and a twenty-five percent increase for lung cancer. RONI CARYN RABIN, The New York Times 06/22/2010

PediaCare Medications Recalled

Four types of PediaCare medicines have been recalled because they were produced at the same plant as contaminated children's Tylenol. Blacksmith Brands, Inc. the producer of PediaCare, stated that the recall was precautionary only. New lots of the medication should ship from another plant in July.

Jury Awards $15 Million in Botox Case

A jury ordered Allergan Inc., the manufacturer of Botox Cosmetic, to pay $15 million to a patient who suffered botulism poisoning due to the product. The jury ruled against Allergan because their Botox did not have adequate information regarding the side effects of the drug on its warning label. Nolan Clay, NewsOK.com 05/12/2010 If you are looking for a Houston Botox attorney, please contact us .

Liver Injury Warning for Xenical and Alli

The FDA has issued a new warning concerning the popular diet drugs known as Xenical (Orlistat) and Alli. The FDA had received reports of severe liver damage associated with the drugs both in the United States and abroad. Some of the patients died from liver failure and others required liver transplants. If you are looking for a Houston diet drug attorney , please contact us .

The FDA's Actos and bladder cancer warning that Texas patients should know

Actos, a widely used drug to treat Type 2 diabetes, has been confirmed as having a strong link to the occurrence of bladder cancer in some users. Actos has been produced and marketed by the Japanese pharmaceutical company, Takeda, for years.

The FDA's Actos and bladder cancer warning that Texas patients should know

Actos, a widely used drug to treat Type 2 diabetes, has been confirmed as having a strong link to the occurrence of bladder cancer in some users. Actos has been produced and marketed by the Japanese pharmaceutical company, Takeda, for years.

FDA issues most serious recall warning for dialysis products GranuFlo, NaturaLyte

Pharmaceutical product recalls are a serious business in the U.S. these days and they are on the rise, as companies flood the consumer market with products that have not been sufficiently tested for dangerous side effects. This applies to products that are supposed to improve our health.

FDA issues most serious recall warning for dialysis products GranuFlo, NaturaLyte

Pharmaceutical product recalls are a serious business in the U.S. these days and they are on the rise, as companies flood the consumer market with products that have not been sufficiently tested for dangerous side effects. This applies to products that are supposed to improve our health.

Tell Us About Your Case Fill Out Our Free Contact Form

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy

Subscribe to this blog's feed FindLaw Network

Office Location

Kennedy Hodges, L.L.P.
711 West Alabama Street
Houston, TX 77006
Local: 713-489-9493
Toll Free: 800-391-9935
Fax: 713-523-1116
Map and Directions

Privacy Policy | Business Development Solutions by FindLaw, a Thomson Reuters business.